Background
Syphilis incidence is rising globally, and higher VDRL titers are linked to increased risk of neurosyphilis. Ocular syphilis (OS), part of the neurosyphilis spectrum, is more common in people with HIV (PWH) than in HIV-negative individuals. Because OS often presents with nonspecific symptoms, diagnosis requires both a reactive VDRL and ophthalmologic confirmation. Data from Latin America on OS in PWH remain limited. We aimed to describe OS prevalence and clinical features in a Mexican cohort of PWH.
Methods
We conducted a retrospective cohort at a Mexico City HIV clinic, including all PWH screened for syphilis from March 2021 to July 2025. OS was defined as a reactive serum VDRL plus ophthalmologic confirmation. Demographic, clinical, virological, and behavioral data were extracted from medical records. Virologic failure (VF) was defined as HIV RNA >200 copies/mL. Comparisons between OS and non-OS cases used nonparametric tests for continuous variables and chi-square or Fisher’s exact tests for categorical variables.
Results
Among 532 syphilis diagnoses in PWH, 25 had OS (4.7%). Incidence was 3% in 2021, 3% in 2022, and declined to <1% thereafter. All OS cases occurred in men, median age was 41 years (IQR 32–50). Median CD4 count was 544 cells/µL (IQR 315–705) and VL 40 copies/mL (IQR 28–2338) at syphilis diagnosis. CSF VDRL was reactive in 12% of cases, fulfilling diagnostic criteria for neurosyphilis, and 8% had otosyphilis. All were hospitalized (median stay 15 days, IQR 14–17), and 80% received IV penicillin.
Compared with non-OS cases, VF was more frequent in OS (24% vs 9.1%, p=0.035). Median VDRL titer was 1:128 in OS vs 1:16 in non-OS (p<0.001). Reinfection rates were similar (60% vs 51%, p=0.51). MSM accounted for 91% of OS cases, and 28% reported drug use, with no significant differences. Median HIV duration was similar (8.8 vs 10.9 years, p=0.79).
Conclusions
OS in PWH correlates with higher VDRL titers and higher occurrence in those with virologic failure, highlighting the importance of HIV control. Despite a decline after 2022, OS remains relevant due to overlap with NS and longer hospitalization. Vigilance, early diagnosis, and improved HIV adherence are crucial to prevent severe outcomes.